Privately-held US biotech Skyhawk Therapeutics has announced a strategic research collaboration with Germany’s Merck KGaA ...

Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a neurology-focused deal with Merck KGaA aimed at discovering small-molecule ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

Merck & Co. and Skyhawk Therapeutics launch a collaboration that could pay the Waltham, MA, biotech approximately $600 million for every small molecule program the companies develop against ...

Merck & Co. has expanded its collaboration with Skyhawk Therapeutics to develop small-molecule drugs that modify RNA splicing in autoimmune and metabolic diseases. The deal builds on an agreement ...

Skyhawk announced Monday that will earn up to $600 million in upfront and potential milestone payments for each molecule it develops for pharmaceutical giant Merck & Co. (NYSE: MRK).

Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today ...